Strategies for the Identification of T Cell–Recognized Tumor Antigens in Hematological Malignancies for Improved Graft-versus-Tumor Responses after Allogeneic Blood and Marrow Transplantation-Reference-Cited by-同舟云学术

Strategies for the Identification of T Cell–Recognized Tumor Antigens in Hematological Malignancies for Improved Graft-versus-Tumor Responses after Allogeneic Blood and Marrow Transplantation

Published:2015-06 Issue:6 Volume:21 Page:1000-1007
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Zilberberg Jenny^ORCID,Feinman Rena,Korngold Robert

Funder

National Institutes of Health

National Heart, Lung, and Blood Institute

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference104 articles.

1. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation;Zeidan;Biol Blood Marrow Transplant,2014

2. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation;Luznik;Cancer Control,2002

3. Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies;Kolb;Curr Opin Oncol,2004

4. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells;Zorn;Clin Cancer Res,2002

5. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature;Blood;2024-03-28

2. Metabolic instruction of the graft-versus-leukemia immunity;Frontiers in Immunology;2024-03-04

3. A retrospective analysis to evaluate if KIR B haplotype donors associate with a reduced risk of relapse in patients with haematological malignancies following haploidentical transplantation at the Blood and Bone Marrow Transplant Unit at Hammersmith Hospital ICHNHST;HLA;2023-09-15

4. MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML;Cancers;2023-08-01

5. T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy;Blood Advances;2023-05-12